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RESUMO
Iodoterapia representa a terapia com iodo radioativo. A radiação beta emitida pelo iodo radioativo são partículas que irão se
armazenar no tecido da tireóide destruindo as células cancerígenas que ainda restaram após a cirurgia (tireoidectomia). É importan-
te enfatizar este possível efeito deletério da terapêutica, a qual afeta a mucosa da via lacrimal, sendo o resultado do processo de
inflamação e cicatrização vascular, produzindo transtornos hipovasculares, hipocelulares e hipóxicos.
Descritores: Obstrução dos ductos lacrimais/etiologia; Dacriocistite;  Radioisótopos do iodo/efeitos adversos; Relatos de casos
ABSTRACT
Iodotherapy represents the radioactive iodine therapy. The beta radiation emitted by radioactive iodine are particles that will be stored in
the thyroid tissue destroying cancer cells that were left after surgery (thyroidectomy). It is important to emphasize a possible deleterious
effect of therapy which affects the mucosa of the lacrimal system which results in a process of vascular inflammation and scarring
producing disorders hypovascular, hypocellular and hypoxic.
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INTRODUCTION
Nasolacrimal duct obstruction in adults(1-3) can be classifiedas primary (which involves a lymphocytic infiltrateculminating in a scarring process) and secondary (due
to various situations such as therapeutic irradiation of
nasopharyngeal carcinoma and basal cell carcinoma of the inner
canthus, radioiodine therapy for thyroid carcinoma, midfacial
fractures, leukaemia, sarcoidosis, tuberculosis, trachoma, Down
syndrome, Stevens-Johnson syndrome, leishmaniasis, Hansen’s
disease, lymphoma, plug migration, and iatrogenic).
The clinical manifestations of nasolacrimal duct obstruction
are epiphora followed by an inflammatory and infectious process
leading to chronic or acute dacryocystitis. The differential
diagnosis of dacryocystitis includes: skin abscess, acute anterior
ethmoiditis, dermoid cyst, cavernous haemangioma, fibroma, and
dacryolithiasis. Mucocele of the lacrimal sac is a chronic
dacryocystitis in which the sac increases in size. It would not
occur without dacryocystitis.(1-3)
Chronic dacryocystitis represents 2-3% of cases of
nasolacrimal duct obstruction.(1-3) According to the literature, the
most frequent causes of nasolacrimal duct obstruction are:
idiopathic (59.2%), congenital (29.6%), iatrogenic (4.5%), and
secondary to radiotherapy (3.7%).(4)
Obstruction after radioiodine therapy is due to the presence
of sodium-iodide transporters in the mucosa of the lacrimal sac
and the nasolacrimal duct, which are areas of anatomic obstruction.
The presence of this receptor explains the fibrosis replacing
epithelial cells of the lacrimal sac after radioiodine therapy.(5,6)
Radioactive iodine is used in the treatment of differentiated
thyroid carcinoma. The aim of treatment is to use the radiation
emitted by iodine to destroy cancer cells that remain after surgery
(thyroidectomy).
The therapy requires hospitalisation for clinical control and to
allow the ingested iodine to be eliminated until radiation levels drop.
Iodine is present in iodised salt found in the diet. Iodine in
salt is of great importance because it is an essential nutrient for the
thyroid gland. The thyroid is located in the front part of the neck
and is responsible for releasing essential hormones for human
metabolism such as T3 (triiodothyronine) and T4 (thyroxine).(7-10)
Radioactive iodine in the form of sodium iodide is produced
by physical processes from iodine found in nature. Because of
its similarity to iodine, radioactive iodine is also captured by the
thyroid, entering the gland’s metabolism. This type of iodine is
called radioactive because it releases two types of radiation:
gamma radiation (similar to X-rays) and beta radiation, which is
used to fight cancer cells that remain in the thyroid. Beta radiation
consists of particles that are stored in thyroid tissue, destroying
cancer cells.(11,12)
Systemic side effects have been reported with high doses.
There have been reports of obstruction of the lacrimal system in
patients undergoing radioiodine therapy, drawing attention to a
possible adverse effect of the therapy.
CASE REPORT
We report a case of bilateral nasolacrimal duct obstruction
in a 42-year-old white female patient. The patient was a married
housewife born in Garanhões (Piaui, Brazil) and living in São
Paulo who underwent total thyroidectomy due to papillary
thyroid carcinoma. She was submitted to radioiodine therapy,
and after 2 years she presented with epiphora in both eyes.
Examination showed a 1.0 vision in both eyes, without
proptosis (Figure 1) and with preserved extraocular muscles.
Biomicroscopy showed no bulbar conjunctival hyperaemia
or anterior chamber reaction, but found a reflux of mucopurulent
discharge in both eyes after compression of the medial part of
the orbit. Milder test: RE, +2; LE, +2 (Figure 2).
Dacryocystography with digital subtraction showed a comple-
te obstruction at the level of Krause’s valve in both eyes (Figure 3).
The patient will undergo bilateral external
dacryocystorhinostomy.
DISCUSSION
In humans, the nasolacrimal ducts are an integral part of the
lacrimal system and are responsible for transporting tears from
the ocular surface to the inferior nasal meatus. Proper functioning
of the lacrimal sac and nasolacrimal duct depends on the
underlying mucosa and muscle layer. Tear flow through the lacri-
mal sac and nasolacrimal duct is highly dependent on interactions
between mucosal mucins, microvilli, and tear fluid.(13-15)
The lacrimal sac and nasolacrimal duct have a different
pattern of mucin gene expression compared to the ocular surface.
Figure 1. Appearance of the patient’s face.
Figure 2. Milder test found +2 in both eyes.
Figure 3. Dacryocystography of both eyes.
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Immunohistochemistry shows that the epithelium of the lacri-
mal sac and nasolacrimal duct produces MUC5B and -7 and, to
a lesser degree, MUC5AC and -2. The pattern of epithelial mucin
seems to change from the ocular surface toward the lacrimal sac.
The nasolacrimal duct was found to produce MUC5B.(13-15)
The diversity of mucins in the lacrimal sac and nasolacrimal
duct may be related to improved tear transportation and
antimicrobial effects. The reduced levels of mRNA for secretory
mucins found in functional dacryostenosis supports the
hypothesis that mucins facilitate tear flow through the
nasolacrimal duct.(13-15)
The Na+/I-symporter (NIS) is a glycoprotein that promotes
iodide uptake by the thyroid gland and several other tissues.
Nasolacrimal duct obstruction has been reported as complication
of radioiodine (I-131) therapy in the treatment of thyroid cancer.
NIS-producing cells were absent and fibrosis was observed in
the nasolacrimal ducts of patients treated with I-131, suggesting
that active iodine uptake mediated by NIS could be responsible
for damage to the nasolacrimal duct.(16-18)
The presence of NIS in columnar epithelial cells of the
lacrimal sac and nasolacrimal duct, sites where obstruction tends
to occur in patients treated with radioiodine therapy, suggests
that NIS may mediate active iodine uptake in these tissues and
may be involved in the pathogenesis of lacrimal obstruction(18).
While high therapeutic doses of radioiodine for thyroid
cancer ablation are generally well tolerated, the therapy is
associated with certain adverse effects. Ophthalmic complications
of therapy include conjunctivitis, dry eye and epiphora(18-26).
Severe complications include necrosis and secondary
infection of previously irradiated tissues. Acute effects usually
involve the oral mucosa. Chronic effects affect the bones and
other mucous membranes, including the lacrimal sac and
nasolacrimal duct mucosa, and result from inflammatory and
scarring processes, leading to hypovascular, hypocellular, and
hypoxic disorders(27).
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